Order Article Reprints

Stellato M, Buti S, Maruzzo M, Bersanelli M, Pierantoni F, De Giorgi U, Di Napoli M, Iacovelli R, Vitale MG, Ermacora P, et al. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International Journal of Molecular Sciences. 2023; 24(2):1096. https://doi.org/10.3390/ijms24021096

Stellato, Marco, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, and et al. 2023. "Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)" International Journal of Molecular Sciences 24, no. 2: 1096. https://doi.org/10.3390/ijms24021096

Stellato, M., Buti, S., Maruzzo, M., Bersanelli, M., Pierantoni, F., De Giorgi, U., Di Napoli, M., Iacovelli, R., Vitale, M. G., Ermacora, P., Malgeri, A., Maiorano, B. A., Prati, V., Mennitto, A., Cavo, A., Santoni, M., Carella, C., Fratino, L., Procopio, G., ... Santini, D. (2023). Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International Journal of Molecular Sciences, 24(2), 1096. https://doi.org/10.3390/ijms24021096